Therefore, while anti-PD-1 treatment showed partial tumor inhibition, the absence of a FAP+CAF-free group limits our ability to definitively attribute reduced immunotherapy efficacy to FAP+CAF-mediated resistance. The gene discussed is FAP; the disease is neoplasm.